AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
CellsBin Closes Series A Financing of Undisclosed Amount Led by 108 BioCapital to Advance Its Rare-Cell Intelligence™ Platform.
CellsBin announced the closing of its Series A financing led by 108 BioCapital. The funding will accelerate commercialization, strategic partnerships, product development, and expansion of CellsBin’s clinical and technical capabilities. The company focuses on building a new observational layer for precision medicine. Its platform aims to help researchers and clinicians understand therapeutic cell behavior and disease evolution.
Company Information
Company
CellsBin
Location
Connecticut, United States
About
CellsBin is pioneering Rare-Cell Biology™ to reveal the rare cells that shape human health. It's Rare-Cell Intelligence™ Platform integrates advanced microfluidics, multimodal imaging, single-cell analysis and artificial intelligence to detect, characterize and monitor rare cells at scale. Through applications in precision diagnostics, therapeutic-cell monitoring and translational research, CellsBin is working to enable smarter decisions, earlier care and better lives.
Fundz sees it the moment CellsBin raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
ConnecticutBiotechnologyHealth CareArtificial IntelligenceHealth Diagnostics